RodneyGillespie

Spelade

  • CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

    CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

    · CCO Oncology Podcast

    In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:

    Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifen

    Presenters:

    Javier Cortes, MD, PhD
    Head, Breast Cancer Program
    IOB Institute of Oncology
    Madrid and Barcelona, Spain

    Stephen R. D. Johnston, MA, FRCP, PhD
    Professor of Breast Cancer Medicine
    Breast Unit
    Department of Medicine
    Royal Marsden Hospital
    London, United Kingdom

    Sara Tolaney, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School
    Associate Director
    Susan F Smith Center for Women’s Cancer
    Director of Clinical Trials, Breast Oncology
    Director of Breast Immunotherapy
    Clinical Research
    Senior Physician
    Breast Oncology Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts, USA

    Content based on an online CME program supported by an educational grant from Lilly.

    Link to full program, including downloadable slides and associated Podcast Pearls PDF:
    https://bit.ly/37tfvtj

  • Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials

    Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials

    · CCO Oncology Podcast

    In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03, and SKYSCRAPER-05.

    Presenters:

    Jyoti D. Patel, MD
    Professor of Medicine
    Division of Hematology and Oncology
    Medical Director for Thoracic Oncology
    Assistant Director for Clinical Research
    Associate Vice Chair of Clinical Research
    Department of Medicine
    Robert H. Lurie Comprehensive Cancer Center
    Northwestern University
    Chicago, Illinois

    Ani Balmanoukian, MD
    Director of Thoracic Oncology
    Medical Oncology
    The Angeles Clinic and Research Institute,
    a Cedars-Sinai Affiliate
    Los Angeles, California

    Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
    https://bit.ly/38qVCH7